Claim OwnershipRounding at Rush
Subscribed: 2Played: 6
Subscribe
© Copyright 2021 All rights reserved.
Description
Rounding at Rush spotlights the work of physicians across the Rush University System for Health, comprised of two community hospitals and Rush University Medical Center, which is ranked by U.S. News & World Report as one of the nation’s best hospitals. As a leading health system, Rush delivers outstanding patient care, offers the latest treatments, educates the next generation of health care providers, and pursues groundbreaking research.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
This activity is being presented without bias and with/without commercial support.
Designation Statement
Rush University Medical Center designates this internet enduring material activity for a maximum of One (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Disclosures
The course director(s), planner(s), faculty and reviewer(s) of this activity have no relevant financial relationships to disclose.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
This activity is being presented without bias and with/without commercial support.
Designation Statement
Rush University Medical Center designates this internet enduring material activity for a maximum of One (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Disclosures
The course director(s), planner(s), faculty and reviewer(s) of this activity have no relevant financial relationships to disclose.
52 Episodes
Reverse
Rush’s skull base surgery program brings specialists from neurosurgery, otolaryngology and other specialties together to care for patients with some of the most complex tumors and disorders of the skull base.
Clinicians review each case in a dedicated multidisciplinary setting to determine the safest and most effective surgical approach. The conversation highlights how Rush incorporates advanced endoscopic and open techniques to reduce operative time, streamline care and prioritize long-term neurologic function and quality of life.
Peter Papagiannopoulos, MD, is an ear, nose and throat doctor at Rush, specializing in rhinology and skull base surgery.
Stephan Munich, MD, is a neurosurgeon and the director of the Skull Base Neurosurgery program at Rush.
Rush University Medical Center’s newly established Dizziness Clinic brings together specialists in otolaryngology, neurology, audiology, and vestibular therapy to evaluate and treat patients with persistent or unexplained dizziness.
Co-directors Mohamed Elrakhawy, MD, an otolaryngologist, and Jesse Taber, MD, a neurologist, discuss how the clinic operates, why cross-disciplinary collaboration matters, and what diagnostic and therapeutic strategies are most effective for this challenging patient population.
Rush University Medical Center offers a comprehensive range of surgical options for patients with drug-resistant epilepsy and complex brain tumors, using advanced techniques that include stereo EEG monitoring, laser ablation, resection, and neuromodulation devices such as responsive nerve stimulation and deep brain stimulation.
Arka Mallela, MD, is an epilepsy neurosurgeon at Rush. He leads the epilepsy surgery and brain mapping practices where he evaluates and treats patients with drug-resistant epilepsy and brain tumors. In addition, Dr. Mallela specializes in removing difficult brain tumors located near areas that control speech, movement and cognition. He uses brain mapping techniques to safely remove as much of the tumor as possible while protecting these important functions.
As a level 4 epilepsy center, Rush University Medical Center meets the highest standards for seizure diagnosis and care. Rush clinicians treat patients with seizures and those who have drug-resistant epilepsy through optimized medical management, surgical evaluation, neuromodulation devices and innovative dietary treatments. Rush also offers specialized programs for women with epilepsy and operates Illinois' only Spanish-speaking epilepsy clinic to address health care disparities in the community.
Antoaneta Balabanov, MD, is a neurologist and chief of the Division of Epilepsy at Rush. In addition to providing medical, surgical and brain stimulation treatments for patients with epilepsy, Dr. Balabanov is involved in research clinical trials in these areas. She has special interest in alternative treatments of epilepsy, especially dietary treatments.
A diverse team of neurovascular specialists in Rush’s Comprehensive Complex Cerebrovascular Clinic provides interdisciplinary, comprehensive care for a variety of cerebrovascular conditions, including intracranial atherosclerosis, Moyamoya disease, carotid stenosis, vertebrobasilar insufficiency, neurovascular dissections and cerebral ischemia.
Stephan Munich, MD, is a neurosurgeon and the director of the Skull Base Neurosurgery program at Rush.
Dixon Yang, MD, MS, is a vascular neurologist who focuses on the diagnosis and management of cerebrovascular diseases.
RUSH MD Anderson Cancer Center’s team of medical oncologists, thoracic surgeons and radiation oncologists works collaboratively to provide patients with advanced, comprehensive care for non-small cell lung cancer.
In this episode of Rounding at Rush, thoracic surgeon Nicole Geissen, DO, medical oncologist Koosha Paydary, MD, and radiation oncologist Gaurav Marwaha, MD, discuss their and other RUSH MD Anderson clinicians’ efforts diagnosing and treating non-small cell lung cancer.
In particular, they talk about RUSH MD Anderson’s novel lung cancer screening program, as well as innovative new therapies RUSH MD Anderson clinicians are using to improve patient outcomes.
1Rush University Medical Center’s neurocritical care team treats patients with complex, emergent neurological conditions, providing them with advanced care that is available 24 hours a day, seven days a week.
In this episode of Rounding at Rush, Rajeev Garg, MD, chief of the Division of Neurocritical Care at Rush, talks about how Rush clinicians collaborate closely with stroke specialists and neurosurgeons to treat patients with a range of severe neurological injuries, including aneurysmal subarachnoid hemorrhage, intracerebral hemorrhage, large ischemic strokes, traumatic brain injuries, status epilepticus and spinal cord injuries.
“Time is brain. The longer an injured brain remains without treatment, the worse the damage and the worse the outcomes. As neurointensivists, our goal is to limit damage to the brain and provide patients the best possible outcomes for recovery.”
Rush cardiologists use sophisticated diagnostic and therapeutic tools and work in a collaborative, interdisciplinary manner to provide superior outcomes for patients with advanced heart failure.
Featured in this episode of Rounding at Rush are Tisha Suboc, MD, a cardiologist and the medical director of Advanced Heart Failure at Rush, and Karolina Marinescu, MD, a cardiologist and the director of the Infiltrative Cardiomyopathy Program at Rush.
“When we see patients, we see them on a continuum,” says Dr. Suboc: When we see them in the hospital, the care doesn’t just stop once they’re discharged. We take care of them from the time they’re in hospital to when they're discharged and follow them long-term.
It’s not just the patients’ heart failure team; they’re seen by their cardiologist, endocrinologist, electrophysiologist and primary care doctor. The multidisciplinary approach we use at Rush has brought us success in managing these types of patients.”
Highly skilled clinicians at RUSH MD Anderson Cancer Center diagnose, treat and prevent all types of skin cancer and other skin conditions. One treatment tool at their disposal is Mohs micrographic surgery, an advanced, minimally invasive and highly effective treatment for skin cancer.
In this podcast, Mariam Mafee, MD, the division chief of Dermatological Surgery at Rush University Medical Center and a Mohs micrographic surgeon at RUSH MD Anderson, discusses how and when to use Mohs surgery, its advantages, as well as how this type of surgery continues to evolve.
“We use appropriate use criteria (AUC), which helps separate less severe from more severe cases of skin cancer. This helps to maximize the utilization of Mohs surgery. We don't use Mohs surgery for every single skin cancer patient or every single skin cancer case. There are times where it really makes sense to be used and times where it doesn't. AUC, which you can find on an app, is a great help with this.”
RUSH MD Anderson Cancer Center’s Breast Cancer Risk Assessment and Personalized Screening Program incorporates sophisticated diagnostic and therapeutic tools that Lisa Stempel, MD, and her colleagues use to determine the most effective care pathway for patients who are at high risk for breast cancer.
Dr. Stempel is a diagnostic radiologist at RUSH MD Anderson. She is chief of the Division of Breast Imaging and director of the High-Risk Cancer Screening Program at RUSH MD Anderson.
“Screening mammography is a great model we can use for early detection for other types of cancers. For example, if we can catch breast cancer in its early stages, say stage 0 or 1, there’s a 99.9% cure rate. Even if it's stage 2, we have a 93% cure rate. Early detection applies to almost all types of cancers, too. What we’ve learned is that with mammography and the addition of supplemental screening tests, we can find breast cancer at the earliest stages.”
The Rush Neurosurgery program is a nationally recognized leader in neurosurgical care, incorporating the most advanced surgical and nonsurgical therapies to treat brain, spine and nervous system conditions. Rush neurosurgeons collaborate with neurologists, neuroradiologists, physiatrists and otolaryngologists to address these conditions, providing patients with individualized and disease-specific approaches in several subspecialty clinics and centers across Chicago and surrounding communities.
Vincent Traynelis, MD, is the interim chair of the Department of Neurosurgery at Rush University Medical Center. He is also the vice chair of academic affairs and the director of the Spine and Peripheral Nerve Section at Rush.
“At Rush, our surgeons are highly trained and specialized in performing skull base surgery. They have the skill set to handle complex tumors and they work hand –in hand with our colleagues in otolaryngology.
They discuss these tumors preoperatively. They consider all of the options. They have the latest equipment. And I believe what sets us apart is that we have the right people with the right focus who can get along and work well together.”
RUSH MD Anderson Cancer Center offers leading-edge treatments for GI cancers, including targeted therapies, immunotherapy, chemotherapy, and minimally invasive surgical options. Our multidisciplinary team of medical oncologists, gastroenterologists, surgical oncologists, colorectal surgeons and interventional radiologists work together to provide our patients with tailored treatment plans to each patient’s specific diagnosis and needs.
Audrey Kam, MD, is the director of GI medical oncology at RUSH MD Anderson, as well as the research director of GI medical oncology at RUSH MD Anderson. She specializes in treating gastrointestinal cancers including colorectal, esophageal, gastrointestinal, liver, pancreatic and stomach cancers.
Sam Pappas, MD, is the Division Chief of Surgical Oncology at Rush University Medical Center. He specializes in treating upper abdominal cancers, including ones in the esophagus, stomach, pancreas, liver and bile duct.
“We love collaborating in immediate proximity to each other within RUSH MD Anderson. This helps to ensure coordinated, multidisciplinary discussions that are patient-focused,” explains Dr. Pappas.
In this episode, Ihsan Kaadan, MD, MS, discusses how he and Rush clinicians provide tailored, wraparound care for patients with peripheral artery disease (PAD) and chronic venous insufficiency. We also profile Dr. Kaadan’s unique role in guiding Rush’s multidisciplinary approach to treat these conditions, where he works with cardiologists, vascular surgeons and interventional radiologists to deliver optimal patient care.
Dr Kaadan is a vascular medicine specialist in the Rush University System for Health; he evaluates and treats patients with complex arterial and vein disorders.
“It’s a one-stop shop at Rush, which sets us apart. A patient can come to the vascular medicine clinic, get evaluated for their disease, then start treatment either with me or one of my colleagues in cardiology or interventional radiology. Patients can also receive cardiac rehab and occupational and physician therapy, so they’re supported throughout their entire experience
At RUSH MD Anderson Cancer Center, oncologists provide patient-centered, cutting-edge care, such as immunotherapies, targeted therapies and minimally invasive surgeries for the treatment of lung cancer. In addition, RUSH MD Anderson clinicians offer patients access to some of the most innovative clinical trials available nationwide.
In this episode, Helen Ross, MD, discusses some of the exciting new clinical trials that Rush is participating in, as well as rising rates of lung cancer in young adults and how to best care for them.
Helen Ross, MD, is a thoracic medical oncologist and an expert in the care of patients with cancers of the chest, including lung cancers, mesothelioma and thymic cancers. Dr. Ross is director of research and clinical trials at RUSH MD Anderson. She is also a professor in the Department of Internal Medicine and serves as interim chief of the Division of Hematology, Oncology and Cellular Therapy.
“We’re only opening clinical trials onsite that are the right fit for our patients. We have an expedited review at RUSH MD Anderson to cut activation time and are working to further reduce that time to bring those trials more quickly to our patients.”
The Rush Cell Therapy Lab provides stem cell transplants, bone marrow transplants and other advanced cell therapy treatments for patients with leukemia, lymphoma, multiple myeloma, and other hematological malignancies. In addition, the lab will soon function as a contracted manufacturing facility partner for the production and quality control and release of cell and gene therapies, representing a significant leap in decentralized hospital based cellular therapeutic manufacturing.
Mahzad Akbarpour, PhD, is the Director of the Rush Cell Therapy Lab at RUSH MD Anderson Cancer Center and is also an Assistant Professor of Internal Medicine in the Division of Hematology, Oncology, and Cell Therapy.
“When CAR-T cells first came on the market a few years ago, Rush was one of the first centers in the nation to provide this therapy to its patients. We’ve also been involved in several clinical trials to advance care and we’ll soon be able to manufacture our own cells on-site.”
The older adult population is the largest-growing cohort of epilepsy patients in the United States. One in four newly diagnosed patients is 65 and older, and that number is set to double by 2055. With the signs of epilepsy presenting in more subtle ways than in younger patients, older adults tend to be late- and mis-diagnosed.
In addition, the geriatric population is often excluded from clinical trials because of age. Thus, this group is underrepresented and its clinical impressions from epilepsy are not well understood.
Rebecca O’Dwyer, MD, is a neurologist and epileptologist in the Rush Epilepsy Center and is the Director of the Epilepsy Clinic for Older Adults at Rush. Her clinical expertise is in epilepsy and cognition, as well as epilepsy and seizures in the older adult population.
“A lot of us in the epilepsy, neurology and lay community associate epilepsy with being a disease of the youth. But we see this bimodal distribution of cases in younger patients as well as older ones. For older adults, epilepsy can present as a symptom of an underlying disorder.”
Danny Luger, MD, is a cardiologist in the Rush University System for Health and the co-founder of the Rush Metabolic Health Consortium.
He runs the Rush Center for Prevention of Cardiovascular Disease at Rush Oak Park whose goal is to prevent patients from developing cardiac disease. When meeting with patients, Dr. Luger helps them identify their barrier to achieving a healthy lifestyle, whether it is sedentary behavior, multiple risk factors for cardiovascular disease, high blood pressure, high cholesterol, or diabetes. After getting to know his patients, he creates individualized medical plans to help them overcome those factors.
“The model that we're trying to put forth is preventive, where we can engage people in health and wellness well before they develop manifestations of disease. Eighty percent of cardiovascular disease is preventable, so we know this is an effective strategy. It's a matter of changing the way that our system approaches chronic diseases and the way that patients conceptualize seeing a doctor.”
With expertise in neurosurgery, neuro-oncology, radiation oncology and palliative care, clinicians in the Rush Spine Tumor Clinic are able to provide patients with comprehensive, tailored treatment plans when they have benign or malignant spinal tumors. Depending on the location and size of the tumor, as well as the patient’s age and overall health, the treatments that Rush provides can help patients regain a better quality of life by lessening their symptoms, such as mobility and memory challenges, pain, speech difficulties and seizures.
John O’Toole, MD, MS, is a neurosurgeon and the co-director of neurosciences service line at Rush, as well as the co-director of the Coleman Foundation Comprehensive Spine Tumor Clinic.
Ken Tatebe, MD, is the clinical director of stereotactic radiosurgery, the neuro-oncology research director and is a radiation oncologist at Rush.
“It can be a struggle for patients to obtain the best care at multiple different institutions, especially when their care providers may not all be on the same page for treatment. We strongly feel that providing this kind of interdisciplinary care under one roof really results in the most optimal treatment plans for patients,” explains Dr. O’Toole.
Endoscopic sleeve gastroplasty (ESG) is a novel, outpatient endoscopic approach to treat obesity. Without using permanent anatomical alterations, clinicians who incorporate ESG into their care suture the inside of the stomach as a way of reducing the stomach’s volume down to the size of a banana, allowing patients to get full faster. In the continuum of weight loss therapies, including medication and surgery, ESG is a viable approach for patients looking for a minimally invasive approach to achieve their weight loss goals.
Christopher Chapman, MD, is a gastroenterologist at RUSH University Medical Center whose expertise is in interventional and bariatric endoscopy, with a focus on providing patients minimally invasive approaches in their care.
“Surgery is a very effective therapy, but is more invasive. Pharmacotherapy, at least before the introduction of GLP-1s, was minimally invasive, but also wasn't as effective [as surgery]. Endoscopy [such as ESG] is in the middle of being a little bit more invasive, but also more effective than medications.”
In this episode, Salina Lee, MD, a gastroenterologist at RUSH University Medical Center, will discuss how the detection and removal of adenomas is key to helping gastroenterologists prevent patients from developing colorectal cancer. Additionally, she will profile several colorectal cancer screening tools, as well as the latest advancements in colonoscopy, including the use of GI Genius that helps to produce higher adenoma detection rates.
“GI Genius is a novel artificial intelligence that's built into our processor to help us identify potential adenomas. You may wonder if GI Genius is helpful even amongst gastroenterologists who already have an adequate, or even good, adenoma detection rate. There’s research that shows it does increase the detection of polyps when compared to humans alone, even if they were considered experienced.”
Comments
Download from Google Play
Download from App Store
United States